A Phase II Study of Brentuximab Vedotin in Combination with Checkpoint Inhibitor CPI Therapy in Subjects with Metastatic Solid Tumors After Progression on Prior PD-1 Inhibitor Treatment

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04609566

Study #:
STUDY00147076

Start Date:
Jan 05, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04609566

View Complete Trial Details & Eligibility at ClinicalTrials.gov